Sun Life ties GLP-1 coverage decisions to the comorbidities behind employers' costliest claims

Sun Life's figures show where catastrophic claims cluster, and its case that GLP-1 coverage reduces them rests on that overlap ^[5][7]. Every comorbidity pairing Sun Life reported from its high-cost book includes cancer ^[5]. The 24% rise counts high-dollar claims that include the drugs ^[1]. Taken at face value, that means GLP-1s are turning up more often inside the most expensive claims. The interview does not report whether members who stayed on the drugs went on to file fewer or cheaper catastrophic claims.

Collier, a registered nurse by training ^[2], argues that employers are putting the drug in the wrong budget line. "Everyone kind of looks at it as a pharmacy expense issue," she said. "But it really should be a cardiometabolic risk strategy. That's how I believe employers should be looking at it." ^[6] She said the metabolic link raises both the count and the size of expensive claims. "The comorbidities and that connection to the metabolic component is really amplifying both the volume of those claims, but also the cost associated with them," she said ^[7]. The article describes hepatic liver disease as one of the conditions GLP-1s can help prevent ^[4].

Any return depends on people staying on the drug, and plan design pulls two ways here. Medical trend has "made a material step up," Collier said, and HR leaders are under pressure to pass more cost to employees ^[15]. People stop for reasons that include side effects ^[13]. When they do, "you're losing out on the value that you would get further down the road after you've taken on the expense," she said ^[12]. Out-of-pocket cost has the same effect. "Most Americans don't have $800, $1,000 in disposable cash," she said ^[14].

Timing matters for anyone deciding this quarter. The drug expense lands in the current plan year. The value Collier describes comes later ^[12]. Sun Life says a stable, long-tenured workforce at a large professional services firm faces a different return calculation from a restaurant or hospitality employer with high turnover ^[16].

A CFO would say the 24% figure supports the pharmacy view: the drugs are adding cost to claims that were already the largest ^[1]. On the evidence published so far, that objection stands. Collier's answer is tighter eligibility, covering members whose body mass index comes with type 2 diabetes, cardiovascular risk or kidney disease ^[11]. Those are the conditions that appear alongside cancer in the high-cost book ^[5]. She also argues that employers cutting or restructuring coverage are deciding without the full actuarial picture ^[10].

In my view, the pharmacy-only critique is right about how big the risk is and not yet about how to price it. Sun Life has shown that the conditions its eligibility rules target sit inside its costliest claims ^[5][11]. Pricing coverage as protection against those claims would take outcome data split by adherence and tenure. Until that exists, the strongest case is for the stable workforce Sun Life describes ^[16].